Story thread · 4 reports / 2 sources

MapLight CEO on what investors missed in the biotech’s schizophrenia data

biopharmadive.com · 12dShare

Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Chris Kroeger sees MapLight's drug as competitive based on the "totality of data."

First report: MapLight’s schizophrenia drug disappoints once-daily hopes despite Phase 2 win — endpts.com, 15d